Replies to post #45020 on Sunshine Biopharma Inc (SBFM)

[EOT]

Holy..... click on the double circle beside “preclinical” and it clearly states

“Phase 1”

[otced]

1. They already tested on Humans and found out it was 16X Stronger https://bciq.biocentury.com/products/adva-27a We are in final stages!!! Any shares bough below 0.0099 Will be a profit even with R/S still along way to 0.0099 LOAD DAILY 1M blocks or 500K BLOCKS
2. FDA right to try SKIPS expensive human trials entirely https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try

[ThoroughBread]

SBFM May 22nd patent filed is the only effective way to deploy the drugs/ medicines to combat Covid19...this is a $30 a share buyout in the makings..
https://www.biocentury.com/article/305451/activ-coming-into-focus-starting-covid-19-therapy-trials-in-june

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership, will start its first trials in June on repurposed immune-modulators and anticoagulants.

In July, two separate trials of monoclonal antibodies (mAbs) will be launched in hospitalized and outpatient COVID-19 patients.

ACTIV, which is led by NIH and managed by the Foundation for NIH, includes 18 biopharma companies, FDA, CDC and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA, the U.S. biodefense preparedness funding agency, is part of ASPR (see “Collaborating to Clobber COVID-19”).

ACTIV is working in parallel with Operation Warp Speed, the U.S. government program that is accelerating the development, manufacturing, procurement and deployment of drugs, vaccines and diagnostics to combat COVID-19.

The scale and urgency of the COVID-19 pandemic are pushing government and industry to collaborate more intensively than has ever been previously attempted.

ACTIV has operated at extraordinary speed, with government officials and corporate scientists collaborating seamlessly, individuals involved in the initiative told BioCentury.

Biopharma executives who are not involved in the effort, however, have complained that it has not been transparent about the criteria for selecting agents to study or its selections.

ACTIV has not publicly disclosed which agents it has selected to test, the timing of its trials, or when readouts can be expected. The documents BioCentury obtained identify classes, but not the specific agents, the consortium plans to test.
First wave of therapies selected

ACTIV has created a process for prioritizing clinical agents for rapid testing and culled through hundreds of agents, including agents submitted by investigators and in surveys conducted by the consortium, as well as from public databases, including databases collated by BioCentury (see BioCentury Coronavirus Resource Center).

[StockRoomBully]

***Fda fast track. Covid Patent 3CLpro, nsp5 Treatment**_

The causative agent of the current COVID-19 global pandemic is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins in infected human cells by cleaving them from two overlapping viral 'polyproteins,' pp1a and pp1ab. One of these functional proteins is a cysteine protease referred to as the main protease (Mpro, also called 3CLpro and nsp5). Mpro cleaves the viral polyproteins' at a number of specific sites thereby generating a multi-subunit protein complex termed viral replicase-transcriptase'. Because of its functional indispensability in viral replication, Mpro is an attractive drug target for the development of a treatment for COVID-19 and other Coronavirus infections," said Dr. Slilaty.

"The kind of small molecules that we're developing are some of the first that are specifically designed for this coronavirus protease," Pegan said. "Up till now, most therapeutic work against SARS has targeted another virulence factor, C3Lpro. This is a great start with a different target. Our hope is that we can turn this into a starting point for creating a drug that we can get in front of the Food and Drug Administration."

"These compounds, naphthalene-based PLpro inhibitors, are shown to be effective at halting SARS-CoV-2 PLpro activity as well as replication. They offer a potential rapid development path to generating PLpro-targeted therapeutics for use against SARS-CoV-2."

https://www.streetinsider.com/dr/news.php?id=16966027&gfv=1

https://www.sciencedaily.com/releases/2020/06/200611133136.htm